MARKET

AIMT

AIMT

Aimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.92
-1.64
-4.49%
After Hours: 35.05 +0.13 +0.37% 19:46 01/17 EST
OPEN
36.80
PREV CLOSE
36.56
HIGH
36.80
LOW
33.68
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
37.00
52 WEEK LOW
16.95
MARKET CAP
2.21B
P/E (TTM)
-9.0321
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AIMT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AIMT News

  • 7 Blockbuster Drugs Expected To Be Launched In 2020
  • Benzinga.8h ago
  • 7 Blockbuster Drugs Expected To Be Launched In 2020
  • Benzinga.8h ago
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About AIMT

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
More

Webull offers Aimmune Therapeutics Inc (AIMT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.